title: Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.
abstract: OBJECTIVE
  To examine plasma levels of visfatin and endogenous secretory receptor for advanced glycation end-products (esRAGE) in diabetic and non-diabetic patients treated with intermittent hemodialysis (IHD), and to explore the possible associations between them, insulin resistance evaluated by homeostasis model assessment for insulin resistance (HOMA-IR), as well as selected biochemical and anthropometric parameters.
  
  
  METHODS
  The study was carried out in 65 IHD patients. Type 2 diabetic patients (n = 28) were included into group I, non-diabetics (n = 37)-into group II. The reference group included 25 healthy volunteers.
  
  
  RESULTS
  There were no significant differences between group I and II in plasma level of visfatin and esRAGE. HOMA-IR was higher in group I than in group II. In both groups these parameters were higher than in healthy subjects. In group I, visfatin correlated with insulin concentration (r = 0.428, P = 0.023), HOMA-IR with esRAGE (r = -0.374, P = 0.049). In group II, esRAGE correlated with waist-to-hip ratio (r = -0.343, P = 0.037), HOMA-IR with body mass index (r = 0.499, P = 0.001) and LDL cholesterol (r = -0.384, P = 0.018).
  
  
  CONCLUSIONS
  Serum concentrations of visfatin and esRAGE are increased in IHD patients. There is no difference in visfatin and esRAGE levels between diabetic and non-diabetic IHD patients. In diabetic IHD patients receiving insulin, lower esRAGE levels are associated with higher insulin resistance, whereas plasma visfatin level is positively related to plasma insulin concentration. Waist-to-height ratio is a significant determinant of plasma visfatin level and HOMA-IR. Insulin resistance seems to be a link between esRAGE and visfatin in IHD diabetics.
authors.affiliation: B. Braun Avitum Poland Dialysis Center, Sienkiewicza str. 3, Nowy Tomyśl 64-300, Poland. leszek.niepolski@avitum.com.pl
authors.forename: Leszek
authors.initials: L
authors.lastname: Niepolski
authors.forename: Alicja E
authors.initials: AE
authors.lastname: Grzegorzewska
authors.forename: Monika
authors.initials: M
authors.lastname: Młot-Michalska
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000097:blood*; D006435:Renal Dialysis; D055815:Young Adult
chemical_list: D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; D054409:Nicotinamide Phosphoribosyltransferase